An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist : Short Wave
Reported by NPR. Read the original →
The headline suggests a connection between Semaglutide, commonly known as Ozempic, and an increase in pregnancies, referred to as an "Ozempic baby boom." It implies that there may be unexpected implications of GLP-1 receptor agonists on fertility or pregnancy rates.
Summarised by a model from NPR's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Human · RCT · 2026
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Human · RCT · 2026
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?Human · Case report · 2026
14 compounds tracked · 373 studies on file · 163 in humans
What the headline doesn't tell you
- Semaglutide has 62 studies on file, 34 of them in humans, the newest published 2026.
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 373 studies between them, 163 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.